Drug maker Gland Pharma said that the United States Food and Drug Administration (US FDA) had inspected the company's API Facility at JNPC, Visakhapatnam, from January 23 to 27, 2023.

The drug maker further informed that the said inspection has been completed with 'zero' observations.

Hyderabad-based Gland Pharma has grown over the years from a contract manufacturer of small-volume liquid parenteral products, to become one of the largest and fastest-growing injectable-focused companies, with a global footprint across 60 countries, including the US, Europe, Canada, Australia, India, and other markets.